Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30773544 | 1.00 | ALDH1A1 (0.39) | ALDH1A1CYP3A4MAPTMEN1GFER | |
| SCHEMBL5820108 | 0.96 | MAPT (0.41) | ALDH1A1CYP3A4MAPTMEN1GFER | |
| SCHEMBL30503607 | 0.83 | MAPT (0.47) | ALDH1A1CYP3A4MAPTMEN1GFER | |
| SCHEMBL9452622 | 0.83 | MAPT (0.47) | ALDH1A1CYP3A4MAPTMEN1GFER | |
| SCHEMBL29375067 | 0.81 | KDM4E (0.41) | ALDH1A1CYP3A4MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4846663 | 0.81 | KDM4E (0.41) | ALDH1A1CYP3A4MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL6610894 | 0.78 | HTR2C (0.48) | ALDH1A1CYP3A4MAPTBCHEACHE | |
| SCHEMBL22188690 | 0.77 | ALDH1A1 (0.48) | ALDH1A1CYP3A4MAPTMEN1GFER | |
| SCHEMBL30042255 | 0.77 | ALDH1A1 (0.48) | ALDH1A1CYP3A4MAPTMEN1GFER | |
| SCHEMBL31731530 | 0.76 | MAPT (0.44) | ALDH1A1CYP3A4MAPTMEN1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113861110-B | Polysubstituted sulfonamide compound, preparation method and medical application thereof | 中国药科大学 | 2024-03-01 | — | — | CN | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| EP-4217348-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BeiGene, Ltd. (KY) | 2023-08-02 | — | — | EP | disclosed |
| CN-116249690-A | Indoline compounds and derivatives as EGFR inhibitors | 百济神州有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2022063106-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEIGENE, LTD. (KY) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022063106-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEIGENE, LTD. (KY) | 2022-03-31 | — | — | WO | disclosed |
| CN-113861110-A | Polysubstituted sulfonamide compound, preparation method and medical application thereof | 中国药科大学 | 2021-12-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | ALDH1A1 3986/4885CYP3A4 2893/4885MAPT 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.